Education
About Us
Working with TipRanks
Follow Us
Qualigen Therapeutics Inc (QLGN)
NASDAQ:QLGN
RESEARCH TOOLSreports
Total Valuation
Qualigen Therapeutics has a market cap or net worth of $2.59M. The enterprise value is $2.86M.
Market Cap$2.59M
Enterprise Value$2.86M
Share Statistics
Qualigen Therapeutics has 736,431 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding736,431
Owned by Insiders―
Owned by Institutions0.02%
Financial Efficiency
Qualigen Therapeutics’s return on equity (ROE) is 6.38 and return on invested capital (ROIC) is 1404.94%.
Return on Equity (ROE)6.38
Return on Assets (ROA)-6.60
Return on Invested Capital (ROIC)1404.94%
Return on Capital Employed (ROCE)5.37
Revenue Per Employee1.30M
Profits Per Employee-3.12M
Employee Count4
Asset Turnover2.56
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Qualigen Therapeutics is -10.39. Qualigen Therapeutics’s PEG ratio is 0.19.
PE Ratio-10.39
PS Ratio0.00
PB Ratio-66.30
Price to Fair Value-66.30
Price to FCF-13.53
Price to Operating Cash Flow-13.53
PEG Ratio0.19
Income Statement
In the last 12 months, Qualigen Therapeutics had revenue of 5.20M and earned -13.42M in profits. Earnings per share was -2.46.
Revenue5.20M
Gross Profit-4.50K
Operating Income-11.30M
Pretax Income-12.48M
Net Income-13.42M
EBITDA-11.30M
Earnings Per Share (EPS)-2.46
Cash Flow
In the last 12 months, operating cash flow was -9.73M and capital expenditures 0.00, giving a free cash flow of -9.73M billion.
Operating Cash Flow-9.73M
Free Cash Flow-9.73M
Free Cash Flow per Share-13.21
Dividends & Yields
Qualigen Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.41
52-Week Price Change-76.61%
50-Day Moving Average3.30
200-Day Moving Average5.94
Relative Strength Index (RSI)53.60
Average Volume (3m)109.23K
Important Dates
Qualigen Therapeutics upcoming earnings date is Aug 13, 2024, TBA Not Confirmed.
Last Earnings DateMay 10, 2024
Next Earnings DateAug 13, 2024
Ex-Dividend Date―
Financial Position
Qualigen Therapeutics as a current ratio of 0.28, with Debt / Equity ratio of -66.99%
Current Ratio0.28
Quick Ratio0.28
Debt to Market Cap<0.01
Net Debt to EBITDA-0.08
Interest Coverage Ratio-7.41
Taxes
In the past 12 months, Qualigen Therapeutics has paid -4.79K in taxes.
Income Tax-4.79K
Effective Tax Rate<0.01
Enterprise Valuation
Qualigen Therapeutics EV to EBITDA ratio is -12.42, with an EV/FCF ratio of -13.62.
EV to Sales26.97
EV to EBITDA-12.42
EV to Free Cash Flow-13.62
EV to Operating Cash Flow-13.62
Balance Sheet
Qualigen Therapeutics has $388.15K in cash and marketable securities with $0.00 in debt, giving a net cash position of $1.05M billion.
Cash & Marketable Securities$388.15K
Total Debt$0.00
Net Cash$1.05M
Net Cash Per Share$1.42
Tangible Book Value Per Share-$0.41
Margins
Gross margin is 0.00%, with operating margin of -217.20%, and net profit margin of -257.79%.
Gross Margin0.00%
Operating Margin-217.20%
Pretax Margin-239.78%
Net Profit Margin-257.79%
EBITDA Margin-217.12%
EBIT Margin-217.20%
Analyst Forecast
The average price target for Qualigen Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-100.00%
EPS Growth Forecast69.07%